Microba Life Sciences has launched its next-generation testing product range, MetaXplore, under Co-Biome, a new brand.

Launched in Australia, the new human gut microbiome testing product range provides diagnostic gastrointestinal health testing and metagenomic-driven gut microbiome analysis to provide healthcare professionals with comprehensive gastrointestinal testing solutions.

The test range can be accessed by healthcare professionals in the country through Co-Biome.

Following its launch in Australia, Microba plans to roll out the product range through its growing worldwide distribution partner network.

Microba Life Sciences CEO Dr Luke Reid said: “The new MetaXplore test range delivers an important advancement in how microbiome test information can be applied in a healthcare setting.

“We continue to make progress at the forefront of this field to advance the application of microbiome testing in a healthcare setting towards a future where it can be routine in health and disease management, much like a blood test is today.”

The MetaXplore test range comprises MetaXplore, MetaXplore GI and MetaXplore GI Plus products.

Key features of the range include an easy-to-interpret report format that is designed for healthcare professionals as well as scientifically graded clinical insights that use guidelines from the National Health and Medical Research Council.

Other features include diagnostic and investigative gastrointestinal health markers, diagnostic pathogen and parasite detection, complete microbiome profiling, and microbiome production and consumption of metabolites.

Microba chief scientific officer associate professor Lutz Krause said: “These new tests integrate traditional gastrointestinal pathology tools with Microba’s next-generation microbiome testing technology and the latest global research to significantly advance the utility of microbiome testing in a healthcare setting.”